The clinical translation of nucleic acid therapeutics , including mRNA, siRNA, and ASO, requires functional delivery vehicles and immunological adjuvants. Throughout the translational process, endosomal escape efficiency, material purity, batch-to-batch consistency, and scale-up feasibility represent the critical bottlenecks in advancing formulations from initial prescription screening to clinical development and commercial manufacturing.

Leveraging our proprietary technology platforms — Phytopower^® Development Platform of Bioactive Molecules & Ingredients from Global Medicinal Plants, Aktinsyn^® Technology Platform of Synthetic Chemistry, and Aktinbio^® Development Platform of Biotechnology, AKTINPHARM® provides professional products and CRDMO services for nucleic acid delivery systems and saponin vaccine adjuvants to global pharmaceutical enterprises, biotech companies, and Marketing Authorization Holders (MAHs).

We integrate natural extraction, chemical synthesis, and biotechnology across the entire continuum from process development to large-scale manufacturing. This covers critical phases such as raw material source oversight, isolation and purification, structural characterization, impurity profiling, process scale-up, and parameter optimization. Focusing on the R&D and production of LNP functional materials, key excipients for nucleic acid delivery systems, and saponin vaccine adjuvants, our services encompass early-stage R&D material preparation, GMP-compliant process development, and commercial-scale supply. We flexibly accommodate diverse phase-specific requirements to accelerate next-generation nucleic acid delivery and vaccine adjuvant projects.

AKTINPHARM^® Nucleic Acid Delivery and Adjuvant Products

▎Ak-HepaPur^® Polyenylphosphatidylcholines (PPC) | CAS: 11096‑62‑1 
Ak‑HepaPur^® Polyenylphosphatidylcholines (PPC) is a phospholipid rich in polyunsaturated fatty acids. It is an important excipient and active ingredient for the preparation of liposomes and liver-targeted drug delivery systems.

▎Ak-HepaPur^® Dioleoyl Phosphatidylcholine (DOPC) | CAS: 4235-95-4 | Molecular Formula: C44H84NO8P
Ak-HepaPur^® Dioleoyl Phosphatidylcholine (DOPC) is a phospholipid and is commonly used alone, or with other components, in the generation of micelles, liposomes and other types of artificial membranes.

▎Ak-HepaPur^® 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) | CAS: 4004-05-1 | Molecular Formula: C41H78NO8P
Ak-HepaPur^® 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)is a neutral helper lipid for cationic liposomes, combining with cationic phospholipids to enhance the transfection efficiency of naked siRNA.

▎Ak-HepaPur^® 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) | CAS: 816-94-4 | Molecular Formula: C44H88NO8P
Ak-HepaPur^® 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)is a lipid used in liposome synthesis and serves as a lipid component in lipid nanoparticle (LNP) systems.

▎Ak-HepaPur^® DMG-PEG 2000 | CAS: 160743-62-4 | Molecular Formula: (C2H4O)nC32H62O5
Ak-HepaPur^® DMG-PEG 2000 is used in the preparation of liposomes for siRNA delivery, where it improves transfection efficiency.

▎EndoSora™ SO 1861 | CAS: 1455278-19-9 | Molecular Formula: C83H129O46
EndoSora™ SO 1861 is a purified saponin functioning as an endosomal escape agent for in vitro research. Endosomal escape is a rate-limiting factor for the intracellular release and functionality of nucleic acids. EndoSora™ SO 1861 serves as a specialized research tool for developing intracellular delivery strategies and evaluating delivery efficiency limitations.

▎Ak‑NucleoVia™ Agrostemmoside E | CAS: 2656438‑29‑6 | Molecular Formula: C84H128O45
Ak‑NucleoVia™ Agrostemmoside E is a patented acetylated triterpenoid derivative sourced from Agrostemma githago. Acting as a gene delivery enhancement carrier, Ak-NucleoVia™ Agrostemmoside E modulates the transfection efficiency of genetic nanopolymers while maintaining cellular tolerance.
Note: Patented products are supplied for scientific research and development purposes only.

▎Q‑Amply^® QS 21 | CAS: 141256‑04‑4 | Molecular Formula: C92H148O46
Q‑Amply^® QS 21 is a purified immunostimulatory saponin derived from the bark of Quillaja saponaria, suitable for mRNA delivery and vaccine adjuvant applications.

▎Q‑Amply^® QS 7｜CAS: 208933-54-4 | Molecular Formula: C83H130O46
Q‑Amply^® QS 7 is a triterpene saponin found in the bark of Quillaja saponaria and immune adjuvant with immune response potentiator activity.

▎Q‑Amply^® QS 17 | CAS: 218138-45-5 | Molecular Formula: C104H168O56
Q‑Amply^® QS 17 is a triterpenoid saponin isolated from the bark of Quillaja saponaria Molina, exhibiting immunoadjuvant activity and inducing mixed Th1/Th2 immune responses .

▎Q‑Amply^® QS 18 | CAS: 836632-59-8 | Molecular Formula: C98H158O51
Q‑Amply^® QS 18 is a triterpenoid saponin isolated from the bark of Quillaja saponaria Molina, exhibiting immunoadjuvant activity.

Production Capacity & Lifecycle Support: From R&D to Commercialization

• R&D Centers: Dedicated to the isolation and purification of botanical active ingredients, QA/QC management, API & formulation CRO services, and the construction of active compound libraries.
• Non-GMP Facility: Focused on early-stage process exploration, route optimization, and non-GMP industrial-scale manufacturing.
• GMP Facility: Powered by a comprehensive QC/QA quality management system to achieve commercial manufacturing of APIs and advanced intermediates, alongside full CRDMO services for innovative drugs.

AKTINPHARM^® integrates discovery, process development, analytics, formulation development, regulatory support, and manufacturing into a unified technological pipeline for synchronized advancement. Through flexible FTE and FFS collaboration models, we support full-scale development needs ranging from non-GMP R&D samples to GMP clinical and commercial supply, as well as from lab-scale and pilot-scale up to commercial manufacturing, catering to our clients' differentiated demands for speed, cost and regulatory compliance at varying stages.

For ongoing projects involving nucleic acid delivery systems or vaccine adjuvants, contact us for technical alignment and to discuss timelines from early-stage screening through clinical materials to commercial supply.

Welcome to meet us: CPHI Milan 2026 from Oct. 6-8, Booth No.: 4H109